Alpine Global Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Alpine Global Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,205	Closed	-$261K	–	262
2023 Q2	$261K	Buy	+1,205	New	+$258K	0.07%	140
2020 Q4	–	Sell	-4,208	Closed	-$325K	–	321
2020 Q3	$325K	Buy	+4,208	New	+$359K	0.07%	130
2020 Q1	–	Sell	-3,253	Closed	-$245K	–	471
2019 Q4	$245K	Buy	+3,253	New	+$142K	0.05%	302

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Alpine Global Management's KRTX Position: Q3 2023 in Review

Alpine Global Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 1,205 shares — an estimated $261K sold.

Alpine Global Management first reported a position in KRTX in Q4 2019 and held it in 3 quarters. The position peaked at $325K in Q3 2020. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

Alpine Global Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Alpine Global Management sold 1,205 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $261K.
Alpine Global Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
Alpine Global Management's Karuna Therapeutics, Inc. Common Stock position peaked at $325K in Q3 2020.
256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Alpine Global Management's 13F filing for Q3 2023, filed 14 Nov 2023.